

[54] **CRACK PREVENTION AND IMPROVED
THROMBOGENICITY OF IMPLANTED
PROSTHESES BY SULFONATION**

[75] Inventor: **Leonard Pinchuk**, Miami, Fla.
[73] Assignee: **Corvita Corporation**, Miami, Fla.
[21] Appl. No.: **63,537**
[22] Filed: **Jun. 18, 1987**

[51] **Int. Cl.⁴** **A61K 2/00**
[52] **U.S. Cl.** **424/423; 424/422;**
424/427; 523/112; 604/266; 623/1; 623/4
[58] **Field of Search** 424/422, 423, 424, 425;
523/112; 604/264, 265, 266, 269

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,273,873 6/1981 Sugitachi et al. 424/422 X
4,378,435 3/1983 Takagi et al. 427/2 X
4,475,972 10/1984 Wong 156/167
4,539,373 9/1985 Mani et al. 525/913 X

OTHER PUBLICATIONS

Pande, "Thermoplastic Polyurethanes as Insulating

Materials for Long-Life Cardiac Pacing Leads", *PACE*, vol. 6, Sep.-Oct. 1983, Part I, pp. 858-867.
Goldberg et al, "Biocompatibility of Intraocular Lens Polymers", Apr. 1985.
Sulfonation and Related Reactions, Chapter 2, pp. 75-77.
Josefowicz et al, "Heparin-Like Biomaterials", Second World Congress on Biomaterials, 1984.

Primary Examiner—Thurman K. Page
Attorney, Agent, or Firm—Lockwood, Alex, Fitzgibbon & Cummings

[57] **ABSTRACT**

Implantable devices for medical use are provided which have been subjected to treatment with a crack preventative/antithrombogenic agent in the form of a sulfate. This treatment substantially prevents surface cracking or fissuring of the subcutaneous implantation as well as preventing thrombus formation along the blood contacting surfaces of the treated material.

30 Claims, 1 Drawing Sheet

